Novel Antibiotic Shows Promise for Community-Acquired Pneumonia (FREE)

By Amy Orciari Herman Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH Oral solithromycin is noninferior to moxifloxacin for the treatment of community-acquired bacterial pneumonia, according to an industry-funded, phase 3 trial published …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news

Related Links:

Abstract Bovine respiratory disease (BRD) remains a major health problem despite extensive use of vaccines during the post-weaning period. Apparent vaccine failure is attributed, in part, to primary vaccination during the period of greatest risk for BRD, providing inadequate time for onset of protective immunity. The current study investigated whether intranasal (IN) vaccination of 3-6 week old calves with a modified-live viral (MLV) vaccine induced sufficient immune memory to prevent respiratory disease and accelerate onset of protective immunity 5 months later. Vaccine groups included naïve controls, a ...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Semin Respir Crit Care Med 2019; 40: 498-507 DOI: 10.1055/s-0039-1696961With the overall improvement in survival of cancer patients and the widespread use of novel immunotherapy drugs for malignant as well as nonmalignant diseases, the prevalence of immunosuppression is rising in the population. Immunocompromised patients are particularly exposed to pulmonary infections which remain a leading cause for acute hypoxic respiratory failure and intensive care unit admission. Although fungal or opportunistic infections are always a concern, bacterial pneumonia remains the most common cause of pulmonary infection, is associated w...
Source: Seminars in Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Tags: Review Article Source Type: research
Conclusions Serum PCT level was not elevated to greater than 0.5 ng/mL in 75% of this cohort of critically ill children with SA admitted to PICU. Presence of CXR infiltrates was not associated with higher PCT levels. Large clinical trials are needed to study the diagnostic and predictive role of PCT in this patient population.
Source: Pediatric Emergency Care - Category: Emergency Medicine Tags: Original Articles Source Type: research
For the first time in more than 15 years, the FDA has approved a systemic antibacterial drug with a novel mechanism of action to combat community-acquired bacterial pneumonia (CABP).
Source: JAMA - Category: General Medicine Source Type: research
PMID: 31567247 [PubMed - in process]
Source: The American Journal of Nursing - Category: Nursing Authors: Tags: Am J Nurs Source Type: research
This noninferiority randomized trial compares the effects of oral lefamulin vs oral moxifloxacin on clinical response at 96 hours among adult patients with community-acquired bacterial pneumonia.
Source: JAMA - Journal of the American Medical Association - Category: General Medicine Source Type: research
Liraglutide (Victoza) is now approved for use in children 10 years and older with type 2 diabetes.Tezacaftor–ivacaftor (Symdeko) is now approved for children six years and older with cystic fibrosis and a specific genetic mutation. Previously, the combination drug was approved for children ages 12 and older.The combination antiinfective ceftolozane–tazobactam (Zerbaxa) is now approved to treat hospital-acquired and ventilator-associated bacterial pneumonia in patients 18 years and older. The dose of ceftolozane–tazobactam is higher for this indication than for others.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research
No abstract available
Source: Critical Care Medicine - Category: Emergency Medicine Tags: Online Letters to the Editor Source Type: research
Source: CEN Case Reports - Category: Urology & Nephrology Source Type: research
We report a case in which the sodium –glucose cotransporter 2 inhibitor, dapagliflozin, contributed to the development of ketosis and sarcopenia in a lean elderly woman with type 2 diabetes. Sodium–glucose cotransporter 2 inhibitor use and reduced β‐cell function together resulted in insulinopenia and probably hyperglucagonem ia, which enhanced proteinolysis and impaired protein synthesis in the muscle, thereby leading to the patient developing sarcopenia. AbstractA 70 ‐year‐old woman with type 2 diabetes was admitted to Gifu University Hospital, Gifu, Japan, because of ketosis. S...
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: Case Report Source Type: research
More News: Avelox | Bacterial Pneumonia | Moxifloxacin | Pneumonia | Primary Care